Neoadjuvant Darovasertib in Primary Uveal Melanoma

Launched by IDEAYA BIOSCIENCES · Jun 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called darovasertib for patients with primary uveal melanoma, which is a type of eye cancer that has not spread to other parts of the body. The trial is in its Phase 3 stage, meaning it will involve a larger group of participants to see how well this treatment works and if it is safe. The study is not yet recruiting participants but will accept individuals aged 65 to 74 who are willing to provide consent and meet certain health criteria.

To be eligible for this trial, participants must have primary non-metastatic uveal melanoma and have good overall health, as assessed by their doctor. They should not have received previous treatment for this type of cancer or have any other serious conditions that would complicate the study. If you join the trial, you can expect regular check-ups and monitoring to see how well the treatment works for you. It's important to know that this study aims to gather more information to help improve future treatments for uveal melanoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Primary non-metastatic uveal melanoma
• • Able and willing to provide written, informed consent before initiation of any study-related procedures, and in the opinion of the Investigator, to comply with all study requirements
• • ECOG 0 or 1
• • Adequate organ function
• Exclusion Criteria:
• • Previous treatment for UM
• • Evidence of metastatic UM
• • Attributes that necessitate enucleation regardless of response to therapy
• • Evidence of progressive secondary underlying ocular disease that would confound longitudinal VA assessments
• • Presence of a malignant disease other than the one being treated in this study